New York City-based The Icahn School of Medicine at Mount Sinai has established a new research center focused on using AI to accelerate drug development.
The AI Small Molecule Drug Discovery Center will integrate AI with traditional drug discovery methods to identify and design small-molecule therapeutics with greater speed and precision, according to an April 2 news release Mount Sinai shared with Becker’s.
The center will focus on three key areas: using generative AI to design novel drug-like molecules, optimizing existing compounds to improve efficacy and safety, and predicting drug-target interactions to repurpose known drugs or natural products for new uses.
Mount Sinai plans to collaborate with pharmaceutical companies, biotech firms and academic institutions to advance drug development efforts.
